Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

• Drug: Tofacitinib
  
  tablets, 5 mg BID x 6 months
• Other: Placebo
  
  tablets, to match tofacitinib 5 mg BID x 3 months
• Drug: Tofacitinib
  
  tablets, 5 mg BID x 3 months

• Experimental: Treatment Sequence A
  
  Tofacitinib 5 mg BID for 6 months
  Intervention: Drug: Tofacitinib
• Placebo Comparator: Treatment Sequence B
  
  Placebo for 3 months then tofacitinib 5 mg BID for 3 months
  Interventions:
  

  • Other: Placebo
  • Drug: Tofacitinib

Inclusion Criteria:

• Chinese patients
• Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3 swollen joints
• Active plaque psoriasis at screening
• Inadequate response to at least one conventional synthetic DMARD

Exclusion Criteria:

• Non-plaque forms of psoriasis (with exception of nail psoriasis)
• History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA